These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8283834)

  • 1. Effect of naloxone on the morphine concentration in the central nervous system and plasma in rats.
    Miyamoto Y; Morita N; Nakamura N; Yamanishi T; Kishioka S; Yamamoto H
    Jpn J Pharmacol; 1993 Oct; 63(2):235-40. PubMed ID: 8283834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.
    Mu RJ; Liu TL; Liu XD; Liu L
    Acta Pharmacol Sin; 2024 Aug; 45(8):1752-1764. PubMed ID: 38570601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal transection reduces both spinal antinociception and CNS concentration of systemically administered morphine in rats.
    Advokat C; Gulati A
    Brain Res; 1991 Aug; 555(2):251-8. PubMed ID: 1933337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of morphine-induced catalepsy by naloxone microinjections into brain regions with high opiate receptor binding: a preliminary report.
    Wilcox RE; Bozarth M; Levitt RA
    Pharmacol Biochem Behav; 1983 Jan; 18(1):51-4. PubMed ID: 6298837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of morphine tolerance and dependence by diazepam and its relation to mu-opioid receptors in the rat brain and spinal cord.
    Tejwani GA; Sheu MJ; Sribanditmongkol P; Satyapriya A
    Brain Res; 1998 Jun; 797(2):305-12. PubMed ID: 9666154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate receptor supersensitivity produced by chronic naloxone treatment: dissociation of morphine-induced antinociception and conditioned taste aversion.
    Bardo MT; Miller JS; Risner ME
    Pharmacol Biochem Behav; 1984 Oct; 21(4):591-7. PubMed ID: 6095324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of antagonism of morphine antinociception by intracerebroventricularly administered naloxone in the rat.
    Porreca F; Cowan A; Tallarida RJ
    Eur J Pharmacol; 1981 Nov; 76(1):55-9. PubMed ID: 7318922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of D1 and D2 dopaminergic receptor kinetics in specific rat brain regions following repeated administration of opiates.
    Elwan MA; Soliman MR
    Pharmacology; 1995 Aug; 51(2):73-83. PubMed ID: 8584575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative properties of plasma corticosterone elevation induced by naloxone-precipitated withdrawal in morphine-dependent rats.
    Kishioka S; Nishida S; Fukunaga Y; Yamamoto H
    Jpn J Pharmacol; 1994 Oct; 66(2):257-63. PubMed ID: 7869610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine.
    Bianchi G; Fiocchi R; Peracchia F; Petrillo P; Tavani A; Manara L
    J Pharm Pharmacol; 1984 May; 36(5):326-30. PubMed ID: 6145770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of morphine on dynorphin B and GABA release in the basal ganglia of rats.
    You ZB; Herrera-Marschitz M; Nylander I; Goiny M; Kehr J; Ungerstedt U; Terenius L
    Brain Res; 1996 Feb; 710(1-2):241-8. PubMed ID: 8963665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphine release and displacement by naloxone in vivo in morphine naive and withdrawn rats.
    Dwoskin LP; Sprague GL; Takemori AE; Sparber SB
    Life Sci; 1980 Feb; 26(5):377-85. PubMed ID: 7189229
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement of opiate-induced depressions in serum luteinizing hormone levels by the prior administration of naloxone in the male rat.
    Cicero TJ; Owens DP; Schmoeker PF; Meyer ER
    Life Sci; 1984 Sep; 35(12):1321-8. PubMed ID: 6090834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opiate receptor antagonism in right-sided congestive heart failure. Naloxone exerts salutary hemodynamic effects through its action on the central nervous system.
    Sakamoto S; Stone CK; Woolf PD; Liang CS
    Circ Res; 1989 Jul; 65(1):103-14. PubMed ID: 2544317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration.
    Pinelli A; Cighetti G; Trivulzio S
    Fundam Clin Pharmacol; 2008 Aug; 22(4):439-45. PubMed ID: 18705754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiarrheal and central nervous system activities of SC-27166 (2-[3 - 5 - methyl - 1, 3, 4 - oxadiazol - 2 - yl) - 3, 3 - diphenylpropyl] - 2 - azabicyclo [2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus.
    Mackerer CR; Brougham LR; East PF; Bloss JL; Dajani EZ; Clay GA
    J Pharmacol Exp Ther; 1977 Dec; 203(3):527-38. PubMed ID: 200732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats.
    Araki H; Kawakami KY; Jin C; Suemaru K; Kitamura Y; Nagata M; Futagami K; Shibata K; Kawasaki H; Gomita Y
    Psychopharmacology (Berl); 2004 Feb; 171(4):398-404. PubMed ID: 13680070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of oxytocin but not corticotrophin-releasing factor-41 into rat hypophysial portal vessel blood can be made opiate dependent.
    Sheward WJ; Coombes JE; Bicknell RJ; Fink G; Russell JA
    J Endocrinol; 1990 Jan; 124(1):141-50. PubMed ID: 2299273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.